Tibolone (Synonyms: 7α-Methyl-Δ5,10-norethindrone, Org OD 14) |
Catalog No.GC41153
One-Click Copy Product Info
|
Tibolone is a synthetic steroid that possesses weak estrogenic, progestational and androgenic properties.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 5630-53-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Tibolone is a synthetic steroid that possesses weak estrogenic, progestational and androgenic properties [1]. The selective local metabolism of Tibolone into the Δ4 metabolite, which has progestogenic properties, prevents endometrial proliferation and negates the requirement for the addition of a progestogen [2]. Tibolone has been widely used in various animal models to alleviate vascular dilation and constriction and to improve the functions of the urinary and reproductive systems[3].
In vitro, Tibolone treatment for 48 hours significantly inhibited the proliferation of MCF-7 cells, with an IC50 value of 0.019μM[4]. Treatment of cells with 10nM Tibolone for 24 hours significantly reduced glucose deprivation-induced cell death in T98G cells and maintained cell morphology, while reducing nuclear fragmentation[5]. Treatment with 10nM Tibolone for 24 hours can reduce the cytotoxicity of 2mM palmitic acid on normal human astrocytes (NHAs) and decrease the loss of cardiolipin[6].
In vivo, Tibolone treatment via oral administration at a dose of 0.04mg/kg/day for 15 days significantly reduced the mean arterial pressure of renal vascular hypertension rats after ovary removal (OVX), albeit lowering total cholesterol and high-density lipoprotein (HDL) cholesterol levels[7]. Oral administration of 1mg/day of Tibolone for three consecutive months can enhance the bone integration process of intramedullary titanium implants in OVX rats, preventing the decline in bone mineral density (BMD) and weight gain after OVX [8].
References:
[1] Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review[J]. Maturitas, 1998, 30(3): 295-305.
[2] Kenemans P, Speroff L, International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines: a report of the International Tibolone Consensus Group[J]. Maturitas, 2005, 51(1): 21-28.
[3] Del Río J P, Molina S, Hidalgo-Lanussa O, et al. Tibolone as hormonal therapy and neuroprotective agent[J]. Trends in Endocrinology & Metabolism, 2020, 31(10): 742-759.
[4] Sookvanichsilp N, Boonleang C, Sookvanichsilp N. Alendronate, raloxifene and tibolone inhibit the proliferation-stimulating activity of 17 (beta)-estradiol in MCF-7 cells[J]. 2005.
[5] Rodriguez M Á, Garcia-Segura L M, Cabezas R, et al. Tibolone protects T98G cells from glucose deprivation[J]. The Journal of steroid biochemistry and molecular biology, 2014, 144: 294-303.
[6] Martin-Jiménez C, González J, Vesga D, et al. Tibolone ameliorates the lipotoxic effect of palmitic acid in normal human astrocytes[J]. Neurotoxicity research, 2020, 38(3): 585-595.
[7] Gilglioni E H, Campos L B, Oliveira M C, et al. Beneficial effects of tibolone on blood pressure and liver redox status in ovariectomized rats with renovascular hypertension[J]. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 2013, 68(5): 510-520.
[8] Apostu D, Lucaciu O, Mester A, et al. Tibolone, alendronate, and simvastatin enhance implant osseointegration in a preclinical in vivo model[J]. Clinical oral implants research, 2020, 31(7): 655-668.
| Cell experiment [1]: | |
Cell lines | T98G cells |
Preparation Method | T98G cells were inoculated into a multi-well plate, and the culture medium was DMEM supplemented with fetal bovine serum (FBS). The cells were cultured for 24 hours. Before treating the cells with Tibolone, a 24-hour serum starvation treatment was performed using DMEM medium without L-glutamine, serum, and phenol red. A 40mM Tibolone stock solution was prepared, with 100% DMSO as the solvent. Then, the Tibolone was diluted in the DMEM medium without L-glutamine, serum, and phenol red. The cells were treated with different concentrations of Tibolone (0, 10, 20, 50, and 70μM) for 24 hours before being treated with palmitic acid. 0.2% DMSO was used as the control for Tibolone. After the Tibolone pretreatment was completed, the culture medium was replaced with 1mM palmitic acid or the control (2.5% BSA and 2mM carnitine), and the cells were cultured for 24 hours. Then, cell viability was detected. |
Reaction Conditions | 0, 10, 20, 50, and 70μM; 24h |
Applications | Tibolone significantly can restore the viability of T98G cells treated with palmitic acid. |
| Animal experiment [2]: | |
Animal models | Female albino Wistar rats |
Preparation Method | Eighty female Wistar albino rats, aged 9-11 weeks and weighing 200±50g, were raised in a standard sterile environment and had not undergone any genetic modification. The rats were housed in an environment with a temperature of 21°C and a 12-hour light/12-hour dark cycle. Standard pellet feed and water were provided, and the rats were allowed to freely consume. The rats were randomly divided into five groups: Group I (control group + ovariectomy), Group II (control group + sham ovariectomy), Group III (alendronate + ovariectomy), Group IV (simvastatin + ovariectomy), and Group V (Tibolone + ovariectomy). Group I and II received no drug treatment and were only provided with free access to food and water. Three months after ovariectomy and sham ovariectomy, bilateral femoral intramedullary nail fixation surgeries were performed on all groups of rats, followed by drug treatment. Three months after the intramedullary nail implantation, bilateral femurs were collected for histological examination. The treatment groups were orally administered medication starting from the first day after surgery and continued for 12 weeks. Group III was given alendronate twice a week at a dose of 3mg/kg; Group IV was given simvastatin daily at a dose of 5mg/kg; Group V was given Tibolone daily at a dose of 1mg/day. |
Dosage form | 1mg/day for 3 months; p.o. |
Applications | Tibolone treatment enhanced the bone integration process of intramedullary titanium implants in OVX rats. |
References: | |
| Cas No. | 5630-53-5 | SDF | |
| Synonyms | 7α-Methyl-Δ5,10-norethindrone, Org OD 14 | ||
| Canonical SMILES | O[C@@]1(C#C)CC[C@@]2([H])[C@]([C@]3([H])CC[C@@]21C)([H])[C@H](C)CC4=C3CCC(C4)=O | ||
| Formula | C21H28O2 | M.Wt | 312.5 |
| Solubility | DMF: 30 mg/ml,DMF:PBS (pH 7.2)(1:3): .25 mg/ml,DMSO: 20 mg/ml,Ethanol: 2 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2 mL | 16 mL | 32 mL |
| 5 mM | 640 μL | 3.2 mL | 6.4 mL |
| 10 mM | 320 μL | 1.6 mL | 3.2 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)